{"id":"eltrombopag-oral-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3989691","moleculeType":"Small molecule","molecularWeight":"564.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eltrombopag binds to the thrombopoietin receptor (MPL) on megakaryocyte progenitor cells in the bone marrow, mimicking the action of endogenous TPO and promoting megakaryocyte proliferation and differentiation. This leads to increased platelet production, thereby raising platelet counts in patients with thrombocytopenia. The drug is a small-molecule, non-peptide TPO receptor agonist that works through a distinct mechanism from other TPO mimetics.","oneSentence":"Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:42.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic immune thrombocytopenia (ITP)"},{"name":"Thrombocytopenia in patients with chronic hepatitis C"},{"name":"Aplastic anemia"}]},"trialDetails":[{"nctId":"NCT04797000","phase":"PHASE2","title":"Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-25","conditions":"Myelodysplastic Syndromes","enrollment":36},{"nctId":"NCT05653219","phase":"PHASE3","title":"A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-02","conditions":"Primary Immune Thrombocytopenia","enrollment":152},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT05466201","phase":"PHASE2, PHASE3","title":"The Use of Eltrombopag Post HSCT in BMFD","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-22","conditions":"Stem Cell Transplant Complications","enrollment":118},{"nctId":"NCT07198672","phase":"NA","title":"Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag","status":"NOT_YET_RECRUITING","sponsor":"Zhenzhen Liu","startDate":"2025-10-31","conditions":"HER2-positive Breast Cancer","enrollment":45},{"nctId":"NCT02773225","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)","status":"COMPLETED","sponsor":"B. Höchsmann","startDate":"2015-01-27","conditions":"Anemia, Aplastic","enrollment":93},{"nctId":"NCT04346654","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-09","conditions":"Immune Thrombocytopenia (ITP)","enrollment":26},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT04638829","phase":"PHASE4","title":"Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2021-03-15","conditions":"Immune Thrombocytopenia","enrollment":60},{"nctId":"NCT03524612","phase":"PHASE2","title":"A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-02","conditions":"Immune Thrombocytopenic Purpura (ITP)","enrollment":105},{"nctId":"NCT03603795","phase":"PHASE2","title":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2018-10-11","conditions":"Acute Myeloid Leukemia","enrollment":110},{"nctId":"NCT06479291","phase":"NA","title":"The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP","status":"RECRUITING","sponsor":"Yunfeng Cheng","startDate":"2024-07","conditions":"Immune Thrombocytopenia With Positive ANA Antibodies","enrollment":126},{"nctId":"NCT05924152","phase":"PHASE1","title":"A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2023-06-29","conditions":"Healthy Adults","enrollment":16},{"nctId":"NCT03718533","phase":"PHASE2","title":"Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-17","conditions":"Poor Graft Function","enrollment":10},{"nctId":"NCT03830749","phase":"PHASE2","title":"Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2018-07-01","conditions":"Immune Thrombocytopenia","enrollment":53},{"nctId":"NCT02998645","phase":"PHASE2","title":"Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-11","conditions":"Severe Aplastic Anemia","enrollment":54},{"nctId":"NCT06045052","phase":"PHASE2","title":"Eltrombopag for Treatment of Fanconi Anemia","status":"COMPLETED","sponsor":"Julian Sevilla","startDate":"2020-12-02","conditions":"Fanconi Anemia","enrollment":8},{"nctId":"NCT01957176","phase":"PHASE4","title":"A Rollover Study to Provide Continued Treatment With Eltrombopag","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-15","conditions":"Thrombocytopaenia","enrollment":22},{"nctId":"NCT04915287","phase":"PHASE4","title":"Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia; Drugs, Chronic Liver Disease","enrollment":476},{"nctId":"NCT02404025","phase":"PHASE2","title":"Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"Aplastic Anemia","enrollment":10},{"nctId":"NCT02201290","phase":"PHASE3","title":"A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06-18","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":9},{"nctId":"NCT02148133","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-23","conditions":"Cytopaenia","enrollment":21},{"nctId":"NCT00909363","phase":"PHASE2","title":"Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-06","conditions":"Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding","enrollment":24},{"nctId":"NCT00828750","phase":"PHASE3","title":"Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05","conditions":"Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic","enrollment":19},{"nctId":"NCT01072162","phase":"PHASE1","title":"Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-12","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":40},{"nctId":"NCT02281370","phase":"PHASE1","title":"Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-05","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":39},{"nctId":"NCT02254434","phase":"PHASE1","title":"A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-28","conditions":"Cirrhosis, Liver","enrollment":26},{"nctId":"NCT01657552","phase":"PHASE1","title":"Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-01","conditions":"Thrombocytopaenia","enrollment":56},{"nctId":"NCT00370331","phase":"PHASE3","title":"RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":197},{"nctId":"NCT01147809","phase":"PHASE2","title":"Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Thrombocytopaenia","enrollment":130},{"nctId":"NCT01830660","phase":"PHASE1","title":"A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-04","conditions":"Healthy","enrollment":96},{"nctId":"NCT00516321","phase":"PHASE3","title":"Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT00110799","phase":"PHASE2","title":"SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SB-497115-GR oral tablets"],"phase":"phase_3","status":"active","brandName":"Eltrombopag oral tablets","genericName":"Eltrombopag oral tablets","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes. Used for Chronic immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C, Aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}